Recombinant Human IL-17RC Isoform 3 Protein, CF Summary
Product Specifications
Leu21-Ala454, with a C-terminal 6-His tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
2269-IL
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS and EDTA. |
Reconstitution | Reconstitute at 200 μg/mL in sterile PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Reconstitution Calculator
Background: IL-17RC
IL-17 receptor C (IL-17 RC; also known as IL-17 RL and IL-17 Rhom) is an 85 - 110 kDa member of the IL-17 receptor family. This is one of five families that currently comprise the cytokine receptor superfamily (1, 2, 3, 4, 5, 6). At this time, there are five members within the IL-17 receptor family, and these are termed IL-17 RA, B, C, D and E. Not all receptors appear to bind known members of the IL-17 cytokine family. To date, IL-17 RA is reported to bind IL-17(A), while IL-17 RB is reported to bind IL-17B and IL-17E (2, 4). Human IL-17 RC is a type I transmembrane glycoprotein that is expressed on a variety of nonhematopoietic cell types. These include endothelial cells (6, 7), chondrocytes and osteoblasts (8), breast and prostatic epithelium (6), and fibroblasts, plus renal tubular epithelium and skeletal muscle cells (8, 9). Full-length IL-17 RC is synthesized as a 791 amino acid (aa) precursor (10, 11). It contains a 20 aa signal sequence, a 518 aa extracellular domain (ECD) (aa 21 - 538), a 21 aa transmembrane segment, and a 232 aa cytoplasmic region. Although IL-17 RA has two fibrinogen-like regions in its ECD that contribute to its function, no such architecture has been identified in the ECD of IL-17 RC (12). Based on studies looking at exon deletions, a key ligand-binding site would appear to exist over aa 425 - 441 (13). The gene for human IL-17 RC contains 19 exons. It is estimated that there are over 90 alternative splice forms, with transmembrane-containing isoforms predominating (6, 14). The full-length isoform is estimated to occur approximately 10% of the time, while the three most common isoforms, as a group, occur about 50% of the time. Based on limited information, alternative splicing appears to regulate ligand specificity (13). R&D Systems IL-17 RC corresponds to IL-17 RC isoform # 3, which shows deletions of aa 36 - 106 and 264 - 278 relative to the full-length form (10). Over the ECD, IL-17 RC isoform #3 is 68% aa identical to mouse IL-17 RC ECD. IL-17 RC is the cognate receptor for IL-17F, and binds IL-17A with similar affinity (13). With IL-17 RA, it forms a definitive receptor for both IL-17A and IL-17F. The stoichiometry is unclear; it may form a heterodimer with IL-17 RA, or a heterotrimer with a preexisting IL-17 RA homodimer (4, 9, 13, 15). The heteromeric nature of the receptor may be important given that the predominant form of the IL-17 cytokine is now considered to be an IL-17A:IL-17F heterodimer (4).
- Gaffen, S.L. et al. (2006) Vitam. Horm. 74:255.
- Weaver, C.T. et al. (2007) Annu. Rev. Immunol. 25:821.
- Moseley, T.A. et al. (2003) Cytokine Growth Factor Rev. 14:155.
- Shen, F. and S.L. Gaffen (2008) Cytokine 41:92.
- You, Z. et al. (2006) Cancer Res. 66:175.
- You, Z. et al. (2007) Neoplasia 9:464.
- Gerritsen, M.E. et al. (2003) Br. J. Pharmacol. 140:595.
- Kokubu, T. et. Al. (2008) J. Hictochem. Cytochem. 56:89.
- Toy, D. et al. (2006) J. Immunol. 177:36.
- GenBank Accession # Q96F46.
- Haudenschild, D. et al. (2002) J. Biol. Chem. 277:4309.
- Kramer, J.M. et al. (2007) J. Immunol. 179:6379.
- Kuestner, R.E. et al. (2007) J. Immunol. 179:5462.
- Haudenschild, D.R. et al. (2006) Prostate 66:1268.
- Kramer, J.M. et al. (2006) J. Immunol. 176:711.
Citation for Recombinant Human IL-17RC Isoform 3 Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide
Sci Rep, 2016-05-17;6(0):26071.
Species: Human
Sample Types: Cell Culture Supernates
Applications: ELISA Development (Detection)
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human IL-17RC Isoform 3 Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human IL-17RC Isoform 3 Protein, CF and earn rewards!
Have you used Recombinant Human IL-17RC Isoform 3 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image